Research focuses on immunotherapy and biotherapeutic design for companion‑animal cancers in a One Health framework. Work spans single‑domain antibody discovery and cost‑efficient expression, PTM‑selective binders, and exosome‑based proteomic biomarkers to predict treatment response.